Iridex (IRIX) Cash & Equivalents (2010 - 2026)

Iridex's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $4.6 million for Q2 2026.

• On a quarterly basis, Cash & Equivalents fell 36.57% year-over-year to $4.6 million in Q2 2026; TTM through Apr 2026 was $4.6 million, a 36.57% decrease from a year earlier, with the FY2026 full-year figure at $6.0 million, up 152.53% from the prior year.
• Cash & Equivalents slipped to $4.6 million in Q2 2026 per IRIX's latest filing, from $6.0 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $23.9 million in Q1 2022 and bottomed at $2.4 million in Q4 2024.
• The 5-year median for Cash & Equivalents is $7.1 million (2023), against an average of $9.7 million.
• Across the five-year window, Cash & Equivalents slumped 66.06% in 2024 and jumped 152.53% in 2026, its largest moves.
• Year by year, Cash & Equivalents stood at $13.9 million in 2022, then slumped by 49.48% to $7.0 million in 2023, then slumped by 66.06% to $2.4 million in 2024, then surged by 133.47% to $5.6 million in 2025, then declined by 17.55% to $4.6 million in 2026.
• Per Business Quant, the three latest IRIX Cash & Equivalents figures stand at $4.6 million (Q2 2026), $6.0 million (Q1 2026), and $5.6 million (Q3 2025).